Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|June 4, 2014
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumabE Zulato, F Bergamo, A De Paoli, et al.
ESMO Open|April 11, 2025
Claudin 18.2: a promising actionable target in biliary tract cancersV Angerilli, D Sacchi, M Rizzato, et al.
Dermatology Online Journal|February 4, 2012
Psoriasis and oral lesions: multicentric study of Oral Mucosa Diseases Italian Group (GIPMO)L Germi, V De Giorgi, F Bergamo, et al.
Research in Microbiology|August 18, 2004
Differentiation of Acidithiobacillus ferrooxidans and A. thiooxidans strains based on 16S-23S rDNA spacer polymorphism analysisRogério F Bergamo, Maria Teresa M Novo, Ricardo V Veríssimo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerF Loupakis, C Cremolini, L Salvatore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)L Fornaro, S Lonardi, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
ESMO Open|February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE studyC Antoniotti, M Carullo, D Rossini, et al.
ESMO Open|July 16, 2021
Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomasV Angerilli, E Fontana, S Lonardi, et al.
ESMO Open|April 17, 2024
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experienceR Moretto, M M Germani, B Borelli, et al.
Pageof 5